According to recent clinical trial results (NCT04164901), vorasidenib’s ability to penetrate the brain and target mutations in IDH1 and IDH2 enzymes showed significantly improved PFS in patients with grade 2 glioma. This evidence concerns the gene IDH1 and central nervous system cancer.